Why 'Watchful Waiting' is Used in CLL Care
- Watchful waiting is a standard, evidence‑supported approach for many people with early‑stage chronic lymphocytic leukemia (CLL). Instead of immediately treating the disease, this approach avoids unnecessary treatment until the disease shows signs of progression.
- Large studies support delaying treatment for asymptomatic CLL patients, many of whom may go years or even decades without needing therapy.
- “The reality is there are a number of patients who don’t require therapy sometimes for five years, 10 years, and beyond that can be managed very effectively just by close monitoring or what we call surveillance,” Dr. Cole Sterling, an oncologist who specializes in hematologic malignancies at Johns Hopkins Medicine in Baltimore, tells SurvivorNet.
- Genetic tests can help estimate disease behavior, but they do not determine when treatment begins, as many patients — regardless of risk markers — can still be safely monitored until there are signs of progression.
Dr. Cole Sterling, an oncologist who specializes in hematologic malignancies at Johns Hopkins Medicine in Baltimore, tells SurvivorNet this is one of the hardest concepts for patients to accept, even though it’s deeply rooted in evidence‑based care.
Read MoreWhy ‘Watchful Waiting’ is Used in CLL
CLL behaves differently from many other cancers because it often grows slowly, and large clinical studies show that starting treatment early does not necessarily improve overall survival compared with waiting until the disease shows signs of progression. Both the National Cancer Institute and American Cancer Society note that most early-stage, asymptomatic CLL patients don’t need treatment right away; many can go years, or even decades, without therapy.“One of the most challenging considerations for patients is this concept of, ‘We’re just going to watch your cancer,'” Dr. Sterling explains, stressing that patients are still closely monitored by medical professionals during “watchful waiting.”
Expert Resources for CLL Patients
Studies show that 30–50% of patients with early‑stage CLL may never require treatment in their lifetime.
“The reality is there are a number of patients who don’t require therapy sometimes for five years, 10 years, and beyond that can be managed very effectively just by close monitoring or what we call surveillance,” Dr. Sterling adds.
A more intensive treatment begins when clear medical criteria are met, such as worsening anemia, rapidly rising lymphocyte counts, bulky lymph nodes, or significant symptoms.
WATCH: Tests That Can Inform the Prognosis of CLL
Watchful monitoring may include:
- Regular blood work
- Physical exams
- Periodic assessments for symptoms such as fatigue, night sweats, enlarged lymph nodes, or infections
Genetic Testing Helps Estimate Risk
Modern CLL care includes genomic testing for markers such as IGHV mutation status, TP53 mutations, and chromosomal deletions (like del(17p)). These help doctors understand how aggressive a patient’s disease might be.
However, Dr. Sterling emphasizes that these tests don’t automatically trigger treatment.
“We can prognosticate through certain genetic tests … but every patient is an individual, and really the best way to know is through time. We’re not currently using those genetic tests to dictate who gets therapy and who doesn’t,” Dr. Sterling says.
Genetic tests help explain how the disease may behave over time and are critical for choosing the right treatment when therapy becomes necessary, but they do not, by themselves, determine when treatment should begin.
The Emotional Side: Coping With Anxiety
Watchful waiting can take a toll on a patient’s mental health. Dr. Sterling says CLL doctors should prioritize addressing this emotional weight, which is just as important as managing the disease itself.
“From the initial conversation, it is critical for helping patients with their mental health and comfort getting through this,” Dr. Sterling explains.
Many patients find relief in knowing that surveillance is structured, evidence‑based, and designed to intervene exactly when treatment will be most effective.
Questions To Ask Your Doctor
- How often will I be monitored if we take a “watch and wait” approach?
- What signs would indicate that it’s time to start treatment?
- What symptoms should I monitor for at home?
- Should I undergo genetic testing?
Learn more about SurvivorNet's rigorous medical review process.
